A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.

作者: Philippe Variol , Laurent Nguyen , Brigitte Tranchand , Christian Puozzo

DOI: 10.1007/S00228-002-0506-X

关键词:

摘要: Abstract Objectives. To develop a population pharmacokinetic (PK) model for simultaneous analysis of oral and intravenous data, to compare the variability between two routes administration vinorelbine, search main patient characteristics that explain this variability, estimate mean bioavailability vinorelbine. Patients methods. A PK was developed from 175 phase I/II patients (419 courses) treated by (20–45 mg/m2) and/or (60–100 mg/m2) vinorelbine given as monotherapy. Oral data were simultaneously fitted using NONMEM program, allowing estimation parameters such factor in who received only formulation. Covariates included demographic characteristics, biological markers, hematological parameters, liver metastases, early vomiting, food intake. The covariate rich sampling (n=187 I then assessed sparse (n=232 II courses). Results. three-compartment best described combined oral/intravenous blood concentration-time data. absolute 36%, with moderate interindividual (CV=20%) intraindividual (CV=19%) variability. Bayesian clearance accurately estimated 180 187 patients. showed comparable at usual doses (25–30 mg/m2 intravenous; CV=26%; 60–80 mg/m2 oral, CV=33%) moderately increased when including maximum tolerated (20–45 mg/m2 intravenous, CV=27%; 60-100 mg/m2 CV=36%). Several relevant relationships influencing total body independent route administration: surface area (proportional relationship), platelet count above 400×109/l (negative correlation), creatinine (positive elevated transaminases correlation). Food intake induced lag time absorption weak poorly relationship observed alkaline phosphatase levels bioavailability, although hepatic markers GGT, LDH, protein, metastases age had no effect on pharmacokinetics. Conclusions. By means (F=36%) its associated estimated. At similar routes. As result identification covariates their confirmation further explorations based limited strategies are now possible. use allows better characterization profile after either vascular or

参考文章(15)
Laurent Nguyen, Brigitte Tranchand, Christian Puozzo, Philippe Variol, Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials British Journal of Clinical Pharmacology. ,vol. 53, pp. 459- 468 ,(2002) , 10.1046/J.1365-2125.2002.01581.X
M D DeMario, M J Ratain, Oral chemotherapy: rationale and future directions. Journal of Clinical Oncology. ,vol. 16, pp. 2557- 2567 ,(1998) , 10.1200/JCO.1998.16.7.2557
Mirte M. Malingré, Jetske M. Meerum Terwogt, Jos H. Beijnen, Hilde Rosing, Franciska J. Koopman, Olaf van Tellingen, Ken Duchin, Wim W. Ten Bokkel Huinink, Martha Swart, Jan Lieverst, Jan H. M. Schellens, Phase I and Pharmacokinetic Study of Oral Paclitaxel Journal of Clinical Oncology. ,vol. 18, pp. 2468- 2475 ,(2000) , 10.1200/JCO.2000.18.12.2468
Jetske M.Meerum Terwogt, Jan H.M. Schellens, Wim W.ten Bokkel Huinink, Jos H. Beijnen, Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treatment Reviews. ,vol. 25, pp. 83- 102 ,(1999) , 10.1053/CTRV.1998.0107
M. O. Karlsson, L. B. Sheiner, The Importance of Modeling Interoccasion Variability in Population Pharmacokinetic Analyses Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 21, pp. 735- 750 ,(1993) , 10.1007/BF01113502
Laurent Nguyen, Etienne Chatelut, Christine Chevreau, Brigitte Tranchand, Isabelle Lochon, Jean-Marc Bachaud, André Pujol, Georges Houin, Roland Bugat, Pierre Canal, Population pharmacokinetics of total and unbound etoposide. Cancer Chemotherapy and Pharmacology. ,vol. 41, pp. 125- 132 ,(1997) , 10.1007/S002800050718
Stéphane Binet, Eric Chaineau, Arlette Fellous, Hedwige Lataste, Anais Krikorian, Jean-Pierre Couzinier, Vincent Meininger, Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. International Journal of Cancer. ,vol. 46, pp. 262- 266 ,(1990) , 10.1002/IJC.2910460220
Isabelle Robieux, Roberto Sorio, Eugenio Borsatti, Renato Cannizzaro, Vinicio Vitali, Paola Aita, Andrea Freschi, Enzo Galligioni, Silvio Monfardini, Pharmacokinetics of vinorelbine in patients with liver metastases Clinical Pharmacology & Therapeutics. ,vol. 59, pp. 32- 40 ,(1996) , 10.1016/S0009-9236(96)90021-1
Tassilo Schilling, HeinerH. Fiebig, Sandor Kerpel-Fronius, B. Winterhalter, Philipp Variol, Patricia Tresca, Bernhard Heinrich, Axel-R Hanauske, Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients Investigational New Drugs. ,vol. 14, pp. 371- 378 ,(1996) , 10.1007/BF00180813
JHM Schellens, GJ Creemers, JH Beijnen, H Rosing, M de Boer-Dennert, M McDonald, B Davies, J Verweij, Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor British Journal of Cancer. ,vol. 73, pp. 1268- 1271 ,(1996) , 10.1038/BJC.1996.243